Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer

About this trial
This is an interventional treatment trial for Breast Carcinoma focused on measuring Trastuzumab, Bevacizumab, Metastatic Breast Cancer, HER2/NEU
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed breast cancer that overexpresses HER-2/NEU with evidence of metastatic disease and/or chest wall recurrence prior to randomization
HER-2/NEU overexpression is defined as 3+ HER-2 positivity as measured by immunohistochemistry OR HER-2 gene amplification as measured by fluorescent in situ hybridization (FISH, e.g. Vysis), per American Society of Clinical Oncology guidelines
- NOTE: representative diagnostic tissue must be submitted for central diagnostic review for confirmation of HER-2/NEU overexpression within two weeks following patient randomization
- Evaluable (measurable or non-measurable) disease is allowed if confirmed within 4 weeks prior to randomization
- Prior endocrine treatment in the adjuvant or metastatic setting is allowed, provided last dose given >= 2 weeks prior to randomization
- Radiation therapy is allowed provided last dose is given >= 3 weeks prior to randomization
- Adjuvant trastuzumab therapy for breast cancer is allowed provided last dose was given >= 12 months prior to diagnosis of recurrence
- Adjuvant or neoadjuvant taxane therapy for breast cancer is allowed provided last dose was given >= 12 months prior to diagnosis of recurrence
- Adjuvant or neoadjuvant therapy with lapatinib is allowed provided last dose is given >= 4 weeks prior to diagnosis of recurrence
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Absolute neutrophil count >= 1,000/mm^3
- Platelet count >= 100,000/mm^3
- Total bilirubin =< 1.5 mg/dL
- Aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN) (=< 5 times normal in patients with known liver involvement)
- Serum creatinine =< 1.5 mg/dL
- Urine protein: creatinine ratio =< 0.5 OR 24-hour urine protein < 1000 mg
- International normalized ratio (INR) =< 1.5 X ULN
- Partial thromboplastin time (PTT) =< 1.5 X ULN
- Multi gated acquisition scan (MUGA) scan or echocardiogram (ECHO) within 6 weeks prior to randomization with an left ventricular ejection fraction (LVEF) above the institutional lower limit of normal
- Patients must be able to understand and provide signed and dated written informed consent
- Major surgical procedure within 4 weeks prior to randomization is not allowed (except for non-operative biopsy, which would not be considered major surgery); treatment can not begin until seven (7) days after placement of a vascular access device
- Women must not be pregnant or breastfeeding; all females of childbearing potential must have a blood or urine test within 2 weeks prior to randomization to rule out pregnancy; women of childbearing potential and sexually active males must use an accepted and effective method of contraception
Patients on full-dose anticoagulants (e.g., warfarin) with PT/INR > 1.5 may be eligible provided that both of the following criteria are met:
- The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
- The patient has not active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- Patients with a concurrent active malignancy except carcinoma in situ of the cervix or non-melanoma skin cancers (unless disease-free for at least 5 years at study entry) are not allowed
Exclusion Criteria:
- Prior chemotherapy, trastuzumab, or bevacizumab for metastatic breast cancer
- Patients who have had a cumulative dose of doxorubicin of greater than 360 mg/m^2 or epirubicin of greater than 640 mg/m^2 in the adjuvant or neo-adjuvant setting at any time
- Patients with grade 2-4 neuropathy
- Patients with a history or radiologic evidence of central nervous system (CNS) disease
- Patients have a current non-healing wound or fracture
- Patients have a hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products or other recombinant human antibodies
- Patients have a serious medical or psychiatric illness that would prevent ability to safely participate or provide informed consent
- Patients using any of the following drugs known to inhibit platelet function are not eligible: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal)
Clinically significant cardiovascular disease, including:
- History of cerebrovascular (CVA) within 6 months
- Uncontrolled hypertension
- Myocardial infarction or unstable angina within 6 months
- New York Heart Association class II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris
- Clinically significant peripheral vascular disease
Sites / Locations
- NEA Baptist Memorial Hospital
- East Bay Radiation Oncology Center
- Eden Hospital Medical Center
- Valley Medical Oncology Consultants-Castro Valley
- Bay Area Breast Surgeons Inc
- Valley Medical Oncology Consultants-Fremont
- Saint Rose Hospital
- Contra Costa Regional Medical Center
- Fremont - Rideout Cancer Center
- Community Hospital of Monterey Peninsula
- El Camino Hospital
- Highland General Hospital
- Alta Bates Summit Medical Center - Summit Campus
- Bay Area Tumor Institute
- Hematology and Oncology Associates-Oakland
- Tom K Lee Inc
- Valley Care Health System - Pleasanton
- Valley Medical Oncology Consultants
- Pomona Valley Hospital Medical Center
- University of California Davis Comprehensive Cancer Center
- Doctors Medical Center- JC Robinson Regional Cancer Center
- The Medical Center of Aurora
- Boulder Community Hospital
- Penrose-Saint Francis Healthcare
- Porter Adventist Hospital
- Exempla Saint Joseph Hospital
- Presbyterian - Saint Lukes Medical Center - Health One
- Rose Medical Center
- Colorado Cancer Research Program NCORP
- Swedish Medical Center
- Saint Mary's Hospital and Regional Medical Center
- North Colorado Medical Center
- Saint Anthony Hospital
- Sky Ridge Medical Center
- Longmont United Hospital
- McKee Medical Center
- Saint Mary Corwin Medical Center
- North Suburban Medical Center
- SCL Health Lutheran Medical Center
- Eastern Connecticut Hematology and Oncology Associates
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Grady Health System
- Emory University/Winship Cancer Institute
- Memorial University Medical Center
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
- Queen's Medical Center
- University of Hawaii Cancer Center
- The Cancer Center of Hawaii-Liliha
- Portneuf Medical Center
- Rush - Copley Medical Center
- MacNeal Hospital and Cancer Center
- Saint Joseph Medical Center
- Illinois CancerCare-Bloomington
- Graham Hospital Association
- Illinois CancerCare-Canton
- Illinois CancerCare-Carthage
- Memorial Hospital
- Hematology and Oncology Associates
- Northwestern University
- John H Stroger Jr Hospital of Cook County
- University of Illinois
- Decatur Memorial Hospital
- Heartland Cancer Research NCORP
- Eureka Hospital
- Illinois CancerCare-Eureka
- NorthShore University HealthSystem-Evanston Hospital
- Galesburg Cottage Hospital
- Illinois CancerCare Galesburg
- Illinois CancerCare-Cottage
- Ingalls Memorial Hospital
- Illinois CancerCare-Havana
- Mason District Hospital
- Hematology Oncology Associates of Illinois-Highland Park
- Hinsdale Hematology Oncology Associates Incorporated
- Hopedale Medical Complex - Hospital
- Midwest Center for Hematology Oncology
- Joliet Oncology-Hematology Associates Limited
- Illinois CancerCare-Kewanee Clinic
- NorthShore Hematology Oncology-Libertyville
- Illinois CancerCare-Macomb
- Mcdonough District Hospital
- Garneau, Stewart C MD (UIA Investigator)
- Porubcin, Michael MD (UIA Investigator)
- Sharis, Christine M MD (UIA Investigator)
- Spector, David MD (UIA Investigator)
- Stoffel, Thomas J MD (UIA Investigator)
- Holy Family Medical Center
- Illinois CancerCare-Monmouth
- Edward Hospital/Cancer Center
- DuPage Medical Group-Ogden
- Illinois Cancer Specialists-Niles
- Bromenn Regional Medical Center
- Community Cancer Center Foundation
- Illinois CancerCare-Community Cancer Center
- Illinois CancerCare-Ottawa Clinic
- Ottawa Regional Hospital and Healthcare Center
- Illinois CancerCare-Pekin
- Pekin Cancer Treatment Center
- Pekin Hospital
- Methodist Medical Center of Illinois
- Proctor Hospital
- Illinois CancerCare-Peoria
- OSF Saint Francis Medical Center
- Illinois CancerCare-Peru
- Illinois Valley Hospital
- Illinois CancerCare-Princeton
- Perry Memorial Hospital
- Hematology Oncology Associates of Illinois - Skokie
- Illinois CancerCare-Spring Valley
- Saint Margaret's Hospital
- Memorial Medical Center
- Carle Cancer Center
- Carle Clinic-Urbana Main
- Franciscan St. Francis Health-Beech Grove
- Elkhart General Hospital
- Indiana University/Melvin and Bren Simon Cancer Center
- Sidney and Lois Eskenazi Hospital
- Saint Vincent Hospital and Health Care Center
- Community Howard Regional Health
- IU Health La Porte Hospital
- IU Health Arnett Cancer Care
- Franciscan Saint Anthony Health-Michigan City
- Saint Joseph Regional Medical Center-Mishawaka
- Reid Hospital and Health Care Services
- Memorial Hospital of South Bend
- South Bend Clinic
- Northern Indiana Cancer Research Consortium CCOP
- McFarland Clinic PC-William R Bliss Cancer Center
- Constantinou, Costas L MD (UIA Investigator)
- Genesis Medical Center - East Campus
- Genesis Medical Center - West Campus
- Mercy Capitol
- Iowa Methodist Medical Center
- Iowa-Wide Oncology Research Coalition NCORP
- Medical Oncology and Hematology Associates-Des Moines
- Medical Oncology and Hematology Associates-Laurel
- Mercy Medical Center - Des Moines
- Iowa Lutheran Hospital
- Siouxland Regional Cancer Center
- Mercy Medical Center-Sioux City
- Saint Luke's Regional Medical Center
- Covenant Medical Center
- Hospital District Sixth of Harper County
- Cancer Center of Kansas - Chanute
- Cancer Center of Kansas - Dodge City
- Cancer Center of Kansas - El Dorado
- Cancer Center of Kansas - Fort Scott
- Cancer Center of Kansas-Independence
- Cancer Center of Kansas-Kingman
- Lawrence Memorial Hospital
- Cancer Center of Kansas - Newton
- Cancer Center of Kansas - Parsons
- Cancer Center of Kansas - Pratt
- Cancer Center of Kansas - Salina
- Stormont-Vail Regional Health Center
- Saint Francis Hospital and Medical Center - Topeka
- Cancer Center of Kansas - Wellington
- Associates In Womens Health
- Cancer Center of Kansas-Wichita Medical Arts Tower
- Cancer Center of Kansas - Main Office
- Via Christi Regional Medical Center
- Wichita NCI Community Oncology Research Program
- Cancer Center of Kansas - Winfield
- Baton Rouge General Medical Center
- Mary Bird Perkins Cancer Center
- Interim LSU Public Hospital
- Louisiana State University Health Science Center
- Eastern Maine Medical Center
- York Hospital
- Greater Baltimore Medical Center
- Memorial Hospital at Easton - Shore Regional Cancer Center
- The Memorial Hospital at Easton
- Bixby Medical Center
- Hickman Cancer Center
- Saint Joseph Mercy Hospital
- Michigan Cancer Research Consortium CCOP
- Oakwood Hospital and Medical Center
- Wayne State University/Karmanos Cancer Institute
- Saint John Hospital and Medical Center
- Green Bay Oncology - Escanaba
- Hurley Medical Center
- Genesys Regional Medical Center-West Flint Campus
- Green Bay Oncology - Iron Mountain
- Allegiance Health
- Sparrow Hospital
- Saint Mary Mercy Hospital
- Mercy Memorial Hospital
- Toledo Clinic Cancer Centers-Monroe
- Saint Joseph Mercy Oakland
- Saint Joseph Mercy Port Huron
- Saint Mary's of Michigan
- Lakeland Hospital
- Saint John Macomb-Oakland Hospital
- Fairview Ridges Hospital
- Mercy Hospital
- Essentia Health Cancer Center
- Essentia Health Saint Mary's Medical Center
- Miller-Dwan Hospital
- Fairview-Southdale Hospital
- Unity Hospital
- Hutchinson Area Health Care
- Meeker County Memorial Hospital
- Minnesota Oncology Hematology PA-Maplewood
- Saint John's Hospital - Healtheast
- Abbott-Northwestern Hospital
- Virginia Piper Cancer Institute
- Hennepin County Medical Center
- North Memorial Medical Health Center
- Mayo Clinic
- Metro Minnesota Community Oncology Research Consortium
- Park Nicollet Clinic - Saint Louis Park
- Regions Hospital
- Saint Joseph's Hospital - Healtheast
- United Hospital
- Saint Francis Regional Medical Center
- Ridgeview Medical Center
- Minnesota Oncology and Hematology PA-Woodbury
- Woodwinds Health Campus
- Southeast Missouri Hospital
- Capital Regional Medical Center
- Mercy Hospital-Joplin
- Washington University School of Medicine
- Missouri Baptist Medical Center
- Center for Cancer Care and Research
- Cancer Research for the Ozarks NCORP
- Mercy Hospital Springfield
- Montana Cancer Consortium NCORP
- Northern Rockies Radiation Oncology Center
- Saint Vincent Healthcare
- Frontier Cancer Center and Blood Institute-Billings
- Billings Clinic Cancer Center
- Bozeman Deaconess Cancer Center
- Bozeman Deaconess Hospital
- Saint James Community Hospital and Cancer Treatment Center
- Benefis Healthcare- Sletten Cancer Institute
- Berdeaux, Donald MD (UIA Investigator)
- Great Falls Clinic
- Northern Montana Hospital
- Saint Peter's Community Hospital
- Glacier Oncology PLLC
- Kalispell Medical Oncology
- Kalispell Regional Medical Center
- Community Medical Hospital
- Montana Cancer Specialists
- Saint Patrick Hospital - Community Hospital
- Guardian Oncology and Center for Wellness
- CHI Health Good Samaritan
- Portsmouth Regional Hospital
- Morristown Medical Center
- Overlook Hospital
- Inspira Medical Center Vineland
- Albert Einstein College of Medicine
- Montefiore Medical Center - Moses Campus
- Roswell Park Cancer Institute
- Orange Regional Medical Center
- Interlakes Foundation Inc-Rochester
- University of Rochester
- State University of New York Upstate Medical University
- Mission Hospital-Memorial Campus
- Cape Fear Valley Health System
- Gaston Memorial Hospital
- Wayne Memorial Hospital
- Margaret R Pardee Memorial Hospital
- Mid Dakota Clinic
- Saint Alexius Medical Center
- Sanford Bismarck Medical Center
- Mary Rutan Hospital
- Toledo Clinic Cancer Centers-Bowling Green
- Mercy Medical Center
- Adena Regional Medical Center
- Case Western Reserve University
- North Coast Cancer Care-Clyde
- Riverside Methodist Hospital
- Columbus NCI Community Oncology Research Program
- Grant Medical Center
- Mount Carmel Health Center West
- Doctors Hospital
- Grandview Hospital
- Good Samaritan Hospital - Dayton
- Miami Valley Hospital
- Samaritan North Health Center
- Dayton NCI Community Oncology Research Program
- Veteran Affairs Medical Center
- Grady Memorial Hospital
- Hematology Oncology Center Incorporated
- Blanchard Valley Hospital
- Atrium Medical Center-Middletown Regional Hospital
- Wayne Hospital
- Kettering Medical Center
- Fairfield Medical Center
- Lima Memorial Hospital
- Marietta Memorial Hospital
- Saint Luke's Hospital
- Toledo Clinic Cancer Centers-Maumee
- Toledo Radiation Oncology at Northwest Ohio Onocolgy Center
- Licking Memorial Hospital
- Saint Charles Hospital
- Toledo Clinic Cancer Centers-Oregon
- North Coast Cancer Care
- Springfield Regional Medical Center
- Flower Hospital
- Mercy Hospital of Tiffin
- The Toledo Hospital/Toledo Children's Hospital
- Saint Vincent Mercy Medical Center
- University of Toledo
- Toledo Community Hospital Oncology Program CCOP
- Mercy Saint Anne Hospital
- Toledo Clinic Cancer Centers-Toledo
- Upper Valley Medical Center
- Fulton County Health Center
- Saint Ann's Hospital
- Clinton Memorial Hospital
- Greene Memorial Hospital
- Genesis Healthcare System Cancer Care Center
- Cancer Care Associates
- Providence Milwaukie Hospital
- Providence Portland Medical Center
- Western Oncology Research Consortium
- Adventist Medical Center
- Providence Saint Vincent Medical Center
- Doylestown Hospital
- Lancaster General Hospital
- Pottstown Memorial Medical Center
- Penn State Health Saint Joseph Medical Center
- Grand View Hospital
- Hematology and Oncology Associates of Rhode Island Inc
- Kent County Hospital
- Avera Saint Luke's Hospital and Cancer Center
- Erlanger Medical Center
- University of Tennessee Health Science Center
- Vanderbilt University/Ingram Cancer Center
- Zale Lipshy University Hospital
- Clements University Hospital
- UT Southwestern/Simmons Cancer Center-Dallas
- Scott and White Memorial Hospital
- Danville Regional Medical Center
- Fredericksburg Oncology Inc
- PeaceHealth Saint Joseph Medical Center
- Harrison HealthPartners Hematology and Oncology-Bremerton
- Kadlec Clinic Hematology and Oncology
- Harborview Medical Center
- Minor and James Medical PLLC
- Fred Hutchinson Cancer Research Center
- Group Health Cooperative-Seattle
- Swedish Medical Center-First Hill
- The Polyclinic
- University of Washington Medical Center
- Cancer Care Northwest - Spokane South
- PeaceHealth Southwest Medical Center
- West Virginia University Charleston
- West Virginia University Healthcare
- Camden-Clark Memorial Hospital
- Langlade Hospital and Cancer Center
- Marshfield Clinic Cancer Center at Sacred Heart
- Sacred Heart Hospital
- Green Bay Oncology at Saint Vincent Hospital
- Saint Vincent Hospital
- Green Bay Oncology Limited at Saint Mary's Hospital
- Saint Mary's Hospital
- UW Cancer Center Johnson Creek
- Dean Hematology and Oncology Clinic
- University of Wisconsin Hospital and Clinics
- Bay Area Medical Center
- Saint Joseph's Hospital
- Green Bay Oncology - Oconto Falls
- Marshfield Clinic at James Beck Cancer Center
- Marshfield Clinic-Rice Lake Center
- Saint Michael's Hospital
- Green Bay Oncology - Sturgeon Bay
- Diagnostic and Treatment Center
- Aspirus UW Cancer Center
- Marshfield Clinic - Wisconsin Rapids Center
- Welch Cancer Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Arm A (chemotherapy and placebo)
Arm B (chemotherapy and bevacizumab)
INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.